MA30696B1 - Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique - Google Patents

Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique

Info

Publication number
MA30696B1
MA30696B1 MA31646A MA31646A MA30696B1 MA 30696 B1 MA30696 B1 MA 30696B1 MA 31646 A MA31646 A MA 31646A MA 31646 A MA31646 A MA 31646A MA 30696 B1 MA30696 B1 MA 30696B1
Authority
MA
Morocco
Prior art keywords
carbazol
tetrahydro
amino
prostaglandin
acetic derivatives
Prior art date
Application number
MA31646A
Other languages
English (en)
Inventor
Heinz Fretz
Julien Pothier
Philippe Risch
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA30696B1 publication Critical patent/MA30696B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS DE L'ACIDE (3-AMINO-1,2,3,4-TÉTRAHYDRO-9H-CARBAZOL-9-YL)-ACÉTIQUE DE LA FORMULE I (I) DANS LAQUELLE R1, R2, R3, R4, R5 ET R6 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION, ET LEUR UTILISATION EN TANT QUE MODULATEURS DES RÉCEPTEURS DE LA PROSTAGLANDINE, PLUS PARTICULIÈREMENT COMME MODULATEURS DES RÉCEPTEURS DE LA PROSTAGLANDINE D2, DANS LE TRAITEMENT DE DIVERSES MALADIES ET TROUBLES À MÉDIATION PAR LA PROSTAGLANDINE. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS ET DES PROCÉDÉS PERMETTANT DE LES PRÉPARER.
MA31646A 2006-08-07 2009-02-17 Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique MA30696B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006052723 2006-08-07

Publications (1)

Publication Number Publication Date
MA30696B1 true MA30696B1 (fr) 2009-09-01

Family

ID=38805811

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31646A MA30696B1 (fr) 2006-08-07 2009-02-17 Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique

Country Status (27)

Country Link
US (1) US8143304B2 (fr)
EP (2) EP2316824A1 (fr)
JP (1) JP5220013B2 (fr)
KR (1) KR101411820B1 (fr)
CN (1) CN101500996B (fr)
AR (1) AR062222A1 (fr)
AT (1) ATE530523T1 (fr)
AU (1) AU2007282949B8 (fr)
BR (1) BRPI0715179A2 (fr)
CA (1) CA2658986C (fr)
CL (1) CL2007002274A1 (fr)
CY (1) CY1112276T1 (fr)
DK (1) DK2051962T3 (fr)
ES (1) ES2374321T3 (fr)
HR (1) HRP20120044T1 (fr)
IL (1) IL196891A (fr)
MA (1) MA30696B1 (fr)
MX (1) MX2009001105A (fr)
MY (1) MY147588A (fr)
NO (1) NO20090979L (fr)
NZ (1) NZ574705A (fr)
PL (1) PL2051962T3 (fr)
PT (1) PT2051962E (fr)
RU (1) RU2448092C2 (fr)
SI (1) SI2051962T1 (fr)
TW (1) TWI408126B (fr)
WO (1) WO2008017989A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
CA2594280C (fr) 2004-12-27 2013-04-23 Anja Fecher Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
WO2010008864A2 (fr) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
CA2752981C (fr) 2009-02-24 2013-11-12 Merck Sharp & Dohme Corp. Derives d'indole en tant qu'antagonistes du recepteur crth2
EP2461809A4 (fr) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
AR080703A1 (es) * 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
PE20161177A1 (es) 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (fr) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
CN104402798B (zh) * 2014-10-21 2016-09-14 杭州瑞德化工有限公司 一种3-氨基-1，2，3，4-四氢咔唑的拆分方法
WO2016133793A1 (fr) 2015-02-16 2016-08-25 Merck Sharp & Dohme Corp. Inhibiteurs du facteur ixa
KR20180053345A (ko) 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 결정질 형태
CN112094223B (zh) * 2019-06-18 2023-09-15 华东师范大学 一类脲基四氢咔唑类小分子有机化合物及用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
US5298626A (en) * 1991-01-18 1994-03-29 Hoechst-Roussel Pharmaceuticals Incorporated Select cyclopent[b]indoles
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5350762A (en) * 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
EP1184373A4 (fr) * 1999-04-20 2004-10-20 Meiji Seika Kaisha Composes tricycliques
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
GB2380951C (en) 2001-10-18 2011-09-28 Derek Colin Tolley Filtration of liquid media
WO2003051837A2 (fr) 2001-12-14 2003-06-26 Zentaris Gmbh Derives tetrahydrocarbazol servant de ligands de recepteurs couples aux proteines g (gpcr)
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2004039807A1 (fr) 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine et derives de pyridoindolizine
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
US20070054951A1 (en) 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2004111047A2 (fr) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
WO2005040112A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes a activite antagoniste de pgd2
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CN100584844C (zh) 2004-01-31 2010-01-27 艾克提麦斯医药品有限公司 咪唑[1,2-c]嘧啶基乙酸衍生物
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
JP4861976B2 (ja) * 2004-03-11 2012-01-25 アクテリオン ファーマシューティカルズ リミテッド インドール−１−イル酢酸誘導体
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
KR101213912B1 (ko) 2004-08-26 2012-12-18 액테리온 파마슈티칼 리미티드 Ｃｒｔｈ2 길항제로서의2-설파닐-벤조이미다졸-1-일-아세틱 애시드 유도체
WO2006034419A2 (fr) 2004-09-21 2006-03-30 Athersys, Inc. Acides indole acetiques antagonistes du recepteur crth2 et ses utilisations
EP1814865A4 (fr) 2004-09-21 2009-09-02 Wyeth Corp Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
CA2594280C (fr) * 2004-12-27 2013-04-23 Anja Fecher Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
NZ560513A (en) 2005-02-25 2010-07-30 Ono Pharmaceutical Co Indole compound and use thereof
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
PL1891075T3 (pl) 2005-05-24 2011-12-30 Merck Serono Sa Spiropochodne tricykliczne jako modulatory CRTH2
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP2397476A3 (fr) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Dérivé d'indole doté d'une activité antagoniste de récepteur PGD2
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
EP1932839A4 (fr) 2005-09-06 2014-09-10 Shionogi & Co Dérivé d acide indolécarboxylate ayant une activité à effet antagoniste du récepteur pgd2
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR062222A1 (es) 2008-10-22
CN101500996A (zh) 2009-08-05
AU2007282949B2 (en) 2012-08-30
MY147588A (en) 2012-12-31
IL196891A0 (en) 2009-11-18
CY1112276T1 (el) 2015-12-09
EP2051962A1 (fr) 2009-04-29
MX2009001105A (es) 2009-02-10
AU2007282949B8 (en) 2012-10-04
CL2007002274A1 (es) 2008-04-18
WO2008017989A1 (fr) 2008-02-14
HRP20120044T1 (hr) 2012-02-29
TW200817328A (en) 2008-04-16
IL196891A (en) 2013-07-31
US20100190830A1 (en) 2010-07-29
RU2009107889A (ru) 2010-09-20
EP2316824A1 (fr) 2011-05-04
JP5220013B2 (ja) 2013-06-26
CA2658986A1 (fr) 2008-02-14
JP2010500337A (ja) 2010-01-07
PT2051962E (pt) 2012-01-10
NO20090979L (no) 2009-05-06
CA2658986C (fr) 2014-11-25
DK2051962T3 (da) 2012-01-02
HK1130062A1 (en) 2009-12-18
ATE530523T1 (de) 2011-11-15
US8143304B2 (en) 2012-03-27
RU2448092C2 (ru) 2012-04-20
KR20090047504A (ko) 2009-05-12
AU2007282949A1 (en) 2008-02-14
EP2051962B1 (fr) 2011-10-26
CN101500996B (zh) 2012-07-04
NZ574705A (en) 2011-12-22
BRPI0715179A2 (pt) 2013-06-11
TWI408126B (zh) 2013-09-11
PL2051962T3 (pl) 2012-03-30
SI2051962T1 (sl) 2012-02-29
KR101411820B1 (ko) 2014-06-24
ES2374321T3 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30289B1 (fr) Dérivés d'amines
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31894B1 (fr) Composes organiques
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
TN2009000138A1 (fr) Biaryl-ether-urees
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA31683B1 (fr) Composes et procedes pour moduler fxr
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA29926B1 (fr) Derives de pyrazine